reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation for Parkinson's Research in July 2009.
The Michael J. Fox Foundation for Parkinson’s Research has awarded research teams at nine biotech and pharmaceutical companies a total of $3.8 million for pre-clinical Parkinson’s drug development projects. Funded investigations aim to push forward novel neuroprotective and improved symptomatic therapies as well as new strategies for addressing complications of treatment.
While MJFF accepts applications from industry under all of its programs, the Therapeutics Development Initiative (TDI) — first launched in 2006 — is the Foundation's only industry- xclusive funding stream. It is a key element of MJFF’s strategy to 'de-risk' preclinical PD research for biotech and pharmaceutical companies, thus expanding industry investment in Parkinson's therapeutic development and helping push the most promising research to the next stage.
Read the complete article (pdf)
Visit the Michael J. Fox Foundation website